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Background: Metabolic stroke is the rapid onset of lasting central neurological deficit associated with
decompensation of an underlying metabolic disorder. Glutaric aciduria type I (GA1) is an inherited disorder of lysine
and tryptophan metabolism presenting with metabolic stroke in infancy. The clinical presentation includes bilateral
striatal necrosis and spontaneous subdural and retinal hemorrhages, which has been frequently misdiagnosed as
non-accidental head trauma. The mechanisms underlying metabolic stroke and spontaneous hemorrhage are
poorly understood.
Results: Using a mouse model of GA1, we show that metabolic stroke progresses in the opposite sequence of
ischemic stroke, with initial neuronal swelling and vacuole formation leading to cerebral capillary occlusion. Focal
regions of cortical followed by striatal capillaries are occluded with shunting to larger non-exchange vessels leading
to early filling and dilation of deep cerebral veins. Blood–brain barrier breakdown was associated with displacement
of tight-junction protein Occludin.
Conclusion: Together the current findings illuminate the pathophysiology of metabolic stroke and vascular
compromise in GA1, which may translate to other neurometabolic disorders presenting with stroke.
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Ischemic and hemorrhagic strokes have been extensively
characterized and studied [1,2]. A third type of stroke,
known as metabolic stroke, begins with metabolic dys-
function and leads to a rapid onset of lasting focal brain
lesions in the absence of large vessel rupture or occlu-
sion [3-5]. The mechanism by which global metabolic
dysfunction leads to focal brain injury in metabolic
stroke is not well understood. Pure metabolic stroke is
routinely reported in glutaric, isovaleric, methylmalonic
and propionic acidurias [5]. Additionally, the organic
acidurias have been associated with spontaneous intra-
cranial hemorrhage, suggesting a vascular component
may contribute to brain injury in these disorders [6,7].
The subdural and retinal hemorrhages frequently found
in glutaric aciduria type I (GA1) may be mistaken for
non-accidental head trauma, with severe legal and* Correspondence: wzinnanti@gmail.com
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stated.emotional consequences for families [7,8]. The etiologic
role of vascular pathology in metabolic stroke has not
been previously elucidated.
GA1 provides a prototypical model for metabolic stroke
as more than 90% of children with this disease will experi-
ence bilateral basal ganglia injury if not identified and
treated pre-symptomatically [9,10]. The disorder is caused
by a deficiency of glutaryl-coenzyme-A dehydrogenase
(EC 1.3.99.7; GCDH), inherited as an autosomal recessive
condition [11]. GCDH is required for complete oxidation
of lysine, hydroxylysine and tryptophan. Affected individ-
uals accumulate glutaric and 3-hydroxy-glutaric acids in
the brain, which are believed to play a primary role in the
pathophysiology of the disease. As one of the more com-
mon inherited metabolic disorders, GA1 affects 1:30,000
to 1:100,000 children worldwide [9,12], with an increased
frequency in genetically isolated populations such as Old
Order Amish, Canadian Ojibway Cree natives, Irish Trav-
elers, and native South Africans [10,13-15]. Children with
GA1 typically develop normally through early infancy, but
then may experience an encephalopathic crisis associatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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[11]. Prevention is critical as the encephalopathic crisis
usually results in irreversible bilateral striatal injury with
substantial morbidity including crippling dystonia, chor-
eathetosis and shortened life span [11].
An animal model of GA1 encephalopathy was developed
by providing GCDH-deficient (Gcdh−/−) mice with a high
lysine or protein diet [16]. Recent work with this model
showed age-dependent susceptibility to acute brain injury
similar to human GA1 that was associated with differences
in the amount of brain lysine accumulation and subse-
quent conversion to glutaric acid in 4-week versus 8-week
old Gcdh−/−mice [17]. The young Gcdh−/− mice suffer
seizures, paralysis, hemorrhages, and death within 3-6-
days of lysine or protein diet exposure, with the acute
accumulation of brain glutaric acid at levels found in
human autopsy cases. Encephalopathy in Gcdh−/−mice
was associated with energy deprivation, detected as de-
pletion of α - ketoglutarate (α KG), ATP and phospho-
creatine [17]. Adult (> 8-week old) Gcdh−/− mice
survive after consuming the same high lysine diet, but
all develop bilateral striatal necrosis after 6-weeks [16].
Since the young Gcdh−/− mice develop hemorrhages
and striatal injury similar to human GA1, this model
provides the opportunity to investigate the specific vas-
cular changes associated with an acute encephalopathic
crisis. In the current study we first describe the neuro-
pathology to guide our subsequent investigations, and
then capture the evolution of the metabolic stroke in-
cluding associated perfusion abnormalities. Additionally,
we investigated the effect of metabolic compromise on
the integrity of the blood–brain barrier (BBB), and po-
tential changes in levels of vascular endothelial growth
factor (VEGF) and hypoxia inducible factor 1-alpha
(HIF-1 α). Our current findings detail the mechanism of
brain injury in metabolic stroke and provide detailed evi-
dence linking metabolic dysfunction to specific BBB ab-
normalities in Gcdh−/− mice. These data are likely
translational to patients with GA1 as well as other neu-
rometabolic disorders presenting with stroke.
Methods
Materials
All chemicals were purchased from Sigma (St Louis,
MO, USA) unless otherwise specified.
Animals
Gcdh−/− mice and age-matched wild type (WT) or het-
erozygous (Gcdh−/+) controls, both of mixed C57Bl/6 J
X 129SvEv background [18], were generated from homo-
zygotes maintained at Penn State College of Medicine
(Department of Comparative Medicine) All animal experi-
ments were reviewed and approved in accordance with
IACUC research guidelines set forth by Pennsylvania StateUniversity and the Society for Neuroscience Policy on the
use of animals in neuroscience research as previously de-
scribed [17].Special diets
Diets were purchased from Harland Teklad (Indianapolis,
IN, USA). The standard diet was the Harland Teklad 2018
diet, which is 18% protein and provides 1% lysine by
weight. The protein diet (TD.03637) (70% casein) contains
62% protein, which is 4.7% lysine by weight. The lysine
diet (TD.04412) was prepared by adding free lysine to a
standard diet to achieve 4.7% total lysine. This level of
lysine is not toxic in normal animals [19,20]. All special
diet treated animals were evaluated daily for symptoms as
previously described [16]. In order to reduce the number
of animals used for these experiments, the protein diet
was used for all histology experiments [16]. The lysine
diet, which causes a slower onset of encephalopathy, was
used for MRI experiments to avoid animals being too ill
to be scanned and for long-term studies such as the BBB
protein analysis.Neuropathology
Six 4-week old Gcdh−/−, 3 WT and 3 Gcdh−/+ mice
were sacrificed before starting the diet (0 hour control).
To follow the earliest pathologic events, 36 Gcdh−/−, 3
WT and 3 Gcdh−/+ mice were placed on a high protein
diet at 4-weeks of age. Six Gcdh−/−mice were sacrificed
every 12-hours after starting the diet and 3 WT and 3
Gcdh−/+ mice were sacrificed at 72-hours with the last
6 Gcdh−/− mice. A second group of 36 Gcdh−/−, 6 WT
and 6 Gcdh−/+ mice were placed on the lysine diet at
4-weeks of age and processed similarly. All the above
mice were perfusion fixed and processed for histology
and electron microscopy. Four additional Gcdh−/− mice
were immersion fixed to show in situ red blood cells
and engorged vessels.
All mice were anesthetized with 100 mg/kg pentobarbital
(i.p.), perfused with lactated Ringers (Baxter Deerfield, IL,
USA) followed by 4% paraformaldehyde with 1% glu-
taraldehyde in 0.2 M cacodylate buffer for 15-minutes. For
histology, brains were removed and post-fixed in 4% para-
formaldehyde for 48-hours, and paraffin embedded. For
electron microscopy, brains were removed and post-fixed
for 48-hours in perfusion buffer fixative.Histology
H & E slides were prepared from paraffin embedded
brains. Sequential 10 μm thick coronal sections were
made within 0.5 mm of the Bregma line for sections in-
cluding striatum and between Bregma −1.5 and −2.0 for
sections including hippocampus [21].
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Brains were dissected into cortical, hippocampal or striatal
blocks and embedded in Epon resin. Toluidine blue
stained semithin Sections 1 μm thick were made from
these blocks. Ultrathin sections of 90 nm were then cut
from the same blocks and stained with uranyl acetate and
lead citrate for transmission electron microscopic analysis
using a Philips CM10 transmission electron microscope.
Immunohistochemistry and confocal microscopy
Glial fibrillary acidic protein (GFAP) and occludin (Occl)
were detected using deparaffinized 10 μm thick coronal
brains sections. Sections were blocked with normal
serum and doubled labeled with polyclonal anti-GFAP
(1:500) (Dako, Carpenteria, CA, USA) and monoclonal
anti-Occl (1:200) (Zymed, South San Francisco, CA,
USA). Additional slides were prepared with GFAP label-
ing alone. All incubations were in PBS with normal
serum overnight at 4°C. Double or single labeled slides
were washed separately 3 times each in PBS and incu-
bated with goat anti-rabbit IgG coupled to Cy2 for GFAP
and goat anti-mouse IgG coupled to Cy3 for Occl. Poly-
clonal GFAP alone was detected with goat anti-rabbit
coupled to horseradish peroxidase (all secondary anti-
bodies diluted 1:2000; Jackson ImmunoResearch, West
Grove, PA, USA). All slides were counterstained with
4’,6’-Diamidino-2-phenylindole (DAPI) 0.1 μg/ml in PBS
for 5 minutes. Confocal microscopy was performed
using a Leica TCS SP2 AOBS confocal microscope
(Leica Microsystems Wetzlar, Germany).
Capillary counts
Capillaries were counted under 10× magnification of 1 μm
thick semithin sections prepared as above. Coronal sec-
tions were examined from cortex, bregma zero; hippo-
campus, bregma-2.30 mm; and striatum, bregma zero
according to ‘The Mouse Brain in Stereotaxic Coordi-
nates’ [21]. Total capillaries were counted within a
300 μm × 300 μm square section centered within the tis-
sue sample. Capillaries were identified by the presence of
at least one endothelial cell lining the lumen with identifi-
able nucleus and the correct size of 3–5 μm [22].
Occluded capillaries were counted as collapsed or with
stasis, showing no patent lumen.
Evans blue perfusion
Gcdh−/−, WT and Gcdh−/+ mice were placed on the
normal or high protein diet for up to 72-hours (n = 5 per
diet Gcdh−/−, n = 3 per diet WT or Gcdh−/+). Each ani-
mal was anesthetized as above and then perfused
through the heart with 5% solution of Evans blue in nor-
mal saline for 30-seconds. Animals were sacrificed and
brains were immersion fixed inside the skull for 48-
hours in 4% paraformaldehyde. Brains were examined inwhole and then sectioned under dissecting microscope.
Additional control animals were used with brief (2-3-
seconds) Evans blue injection followed by complete dis-
section to reliably differentiate arterial from venous
structures. Evans blue concentration was measured in
brain samples using spectrophotometry and corrected
for protein content as previously described [23].
Western blot analysis
Brain protein extracts from mice from each treatment
group (20 μg each as determined by Bio-Rad protein
assay, Hercules, CA, USA) were loaded on 10% sodium
dodecyl sulfate-polyacrylamide gels and transferred onto
nitrocellulose membranes, blocked in PBS-Tween 20
(0.1%) containing 5% non-fat dry milk and 0.1% BSA for
1 h at 4°C and incubated with monoclonal antibodies
against Occludin, ZO-1 (both from Zymed, South San
Francisco, CA, USA), Hypoxia inducible factor 1 alpha
(HIF-1α) (RD System, Abingdon, England), vascular endo-
thelial growth factor (VEGF) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or anti phospho-occludin at Ser
490 [24] overnight at 4°C. Blots were washed with PBS-
Tween 20 (0.1%) and incubated with horseradish peroxid-
ase conjugated anti-mouse IgG (1:10,000) for 2 h at 4°C.
Immunoreactive bands were visualized using an enhanced
chemiluminiscence system (ECL; Amersham Biosciences).
Densitometric analysis of immunoreactive bands was per-
formed by using ImageQuant 5.2 software (Amersham
Biosciences) and results were expressed as percentage of
control (WT standard diet). As a loading control we
reprobed the blots with anti-actin (Sigma-Aldrich) in
order to control for small variability in the gel loading.
MRI angiography and perfusion
Magnetic resonance (MR) angiography and perfusion was
performed on a 7.0 T Bruker system using a 2 mm bird-
cage coil. Gcdh−/− and WT mice were imaged at 0, 36, 72
and 96-hours following the start of lysine diet (N = 11
Gcdh−/−, N = 4 WT). Prior to imaging mice were anesthe-
tized with 3% isoflurane, adjusted during the imaging to
1–1.5% in order to maintain a constant breathing rate of
40 bpm. Arterial spin labeling (ASL) was used to acquire a
single-slice perfusion-weighted image at the level of the
striatum (TR/TE = 2000/12 ms, NAX = 2, 1.06 mm slice
thickness, 2082 μm2 in-plane resolution). A RARE se-
quence with multiple TR times (100-5000 ms), same slice
position and resolution, was used to calculate T1 values.
Perfusion values were calculated on a pixel by-pixel basis
using NIH Image J (NIH; rsbweb.nih.gov/ij/) and MRI
analysis calculator, a plug-in written by Karl Schmidt
(NIH; rsbweb.nih.gov/ij/plugins/mri-analysis.html). MR
angiography was done using a 3D gradient recalled echo
sequence (TR/TE = 19/3 ms or TR/TE = 100/3 ms in
order to allow slower moving blood to be visualized,
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projection for image reconstruction.
Statistics
Normally distributed data sets were analyzed by t-test,
ANOVA or ANOVA with repeated measures with Fisher
LSD or Holm-Sidak post-hoc test. Kruskal-Wallis one-
way analysis of variance on ranks was performed with
Student-Neuman-Keuls post hoc test on samples that
were not normally distributed. Sigma Stat software
(Jandel Scientific, San Rafael, CA) was used for analysis.
All p-values less than 0.05 were considered statistically
significant.
Results
Venous congestion and hemorrhage
Four-week old Gcdh-/ -mice placed on an increased lysine
or protein diet were shown previously to develop hemor-
rhages similar to human GA1 [16]. Therefore, we first ex-
amined gross brain specimens from control and Gcdh−/−
mice placed on a standard or protein diet (60% protein) in
order to identify hemorrhage locations. Brief Evans blue
injection was used to differentiate arterial from venous
structures. Pathologic changes were limited to Gcdh−/−
mice on the protein and lysine diet, in which venous dila-
tion and engorgement developed within 36-48-hours.
Enlarged veins were evident on the outer surface of the
brain (Figure 1a). Coronal sections showed substantial en-
largement of internal cerebral veins that drain the caud-
ate/putamen bilaterally (Figure 1b and e). On further
dissection between the hippocampus and thalamus, sym-
metric dilation of the cerebral veins coalesced into a large
dilated great vein of Galen (Figure 1e). These findings are
consistent with a recent report showing that brain injury
in children with GA1 was also associated with enlarge-
ment of the vein of Galen [4].
Microscopic inspection of perfusion fixed brain from
Gcdh−/− mice on the protein diet showed evidence of
hemorrhage (Figure 1f ) and BBB compromise as red
blood cells were found outside the endothelial cell layer
(Figure 1g). Additional immersion fixed brain sections
showed engorgement of larger non-exchange vessels
(Figure 1h and i). Together these pathological changes
suggest early filling of the venous system resulting in in-
creased venous pressure, BBB breakdown and hemorrhage.
Similar findings associated with venous dilation and en-
gorgement have been reported in arteriovenous malfor-
mations where shunting of non-exchange vessels results
in early filling of venous structures [25,26].
Microscopic and ultrastructural changes
Since vessel changes were consistently found in 100% of the
4-week old Gcdh−/−mice after initiation of protein diet, we
examined semi-thin sections from each of 12-hour intervalsafter diet exposure to capture the evolution of this process.
Cortical sections from Gcdh−/− mice on a standard diet
showed slightly increased perivascular spaces around some
capillaries compared to the normal morphology of Gcdh−/+
controls (compare Figure 2a and b). Perivascular spaces
become more pronounced at 24-hours after protein diet
exposure in Gcdh−/− mice (Figure 2c). This change is asso-
ciated with compromise of capillary lumens as some local
axons are edematous. Vacuoles fill axons of large cortical
neurons (Figure 2d). These findings were previously dem-
onstrated as the initial pathologic changes after protein or
lysine diet exposure in Gcdh−/− mouse brain [17]. The
local expansion of these structures impinges on capillaries
with severe compromise of vessel lumens. This process is
further elucidated by GFAP labeling in Gcdh−/− cortical
sections at 36-hours after protein diet exposure (Figure 2e).
GFAP labeling shows intact astrocyte end-feet surround-
ing capillary lumens with severe compromise via locally
expanding vacuoles. These vacuoles are devoid of staining
indicating that they are not of astrocyte origin similar to
previously reported findings [17].
We next used electron microscopy to inspect ultrastruc-
tural changes around brain capillaries at different time
points after protein diet exposure (Figure 3). Multiple capil-
lary lumina in Gcdh−/− mouse brain were compromised
with increasing severity between 24 and 48-hours after pro-
tein diet exposure (Figure 3c-f). Gcdh−/+ and Gcdh−/− cor-
tex after 72 and 12-hours of protein exposure respectively
show normal vessel morphology (Figure 3a and b). In con-
trast, after 24-hours of protein diet, Gcdh−/− cortical capillar-
ies showed compressed lumens impinged by edematous
axons and neuronal projections with swollen mitochondria
(Figure 3c). Higher magnification of similar sections showed
increasing edema of dendrites in local neuropil with swelling
of astrocyte end-feet after 36-hours (Figure 3d). At 36-hours
after protein diet exposure some cortical capillaries show
both intact and swollen astrocyte end-feet with severely
swollen local neuronal projections and further compromise
of capillary lumina (Figure 3e). Swollen astrocyte end-feet
are suggestive of post-ischemic changes within 5-hours of
ischemic event [27]. After 48-hours of protein diet exposure
we observed capillaries that were severely compromised
with surrounding expanded neuronal projections, identi-
fied by synapses with extensive mitochondrial swelling
(Figure 3f). Together these findings confirm our previous
observation that neuronal swelling is the initial patho-
logical change in Gcdh−/− mice exposed to a high protein
diet [17]. In addition we show that neuronal swelling ap-
pears to compromise local capillary lumina.
Ischemic changes in different brain regions
Compromised capillaries were found with variable fre-
quency at different time points in Gcdh−/− mouse brains
after protein diet exposure. In order to characterize the
Figure 1 Vessel changes associated with encephalopathy in Gcdh−/− mice. Dilation of cerebral veins noted near circle of Willis on underside
of Gcdh−/− mouse brain after protein diet exposure (a, black arrow). Brief Evans blue injection highlights arterial vessels of the circle of Willis
(a, white arrow). b Section though cortex at Bregma −2.76 shows dilated left cerebral vein occupying entire space between hippocampus and
thalamus (b, red arrow) with standard diet Gcdh−/− control for comparison (c). d and e shows dorsal aspect of thalamus with overlying cortex
and hippocampus removed. Note extreme dilation of internal cerebral veins (e, red arrow) and great vein of Galen (e, black arrow) with normal
appearing posterior cerebral artery branch marked with Evans blue injection (e, blue arrow). Vein of Galen is barely visible at this magnification in
standard diet Gcdh−/− control (d, red arrow). f Perfusion fixed sections of Gcdh−/− mouse brain 36-hours after protein diet exposure shows venous
congestion below hippocampus with extrusion of blood into CA3 pyramidal cell layer (arrow). g Perivascular collection of red blood cells outside
endothelial layer (thick arrow). Note normal appearing vessel in same region (thin arrow). h and i Striatal sections of immersion fixed brain
show congestion of larger “non-exchange” vessels (white arrows, venuole h and artery i). (e-g, Hematoxylin & eosin of perfusion fixed brain,
scale bars = 200 μm).
Zinnanti et al. Acta Neuropathologica Communications 2014, 2:13 Page 5 of 15
http://www.actaneurocomms.org/content/2/1/13
Figure 2 Neuronal swelling impinges on brain capillaries. Perfusion fixed brain sections from Gcdh−/+ control (a) show normal cortical
neuropil and capillary morphology (black arrows). b Gcdh−/− mice maintained on a standard diet show small lucent regions outside capillaries
(black arrows). c After 24-hours of protein diet, lucent regions become more pronounced (black arrows) associated with swelling and edema of
cortical axons (white arrows). d Gcdh−/− cortex shows vacuoles filling axon of large cortical neuron (white arrows) impinging on capillaries (black
arrows) with some showing stasis at 24-hours. e Section of cortex from Gcdh−/− mouse 36-hours after protein diet showing large vacuoles (white
arrows) impinging on blood vessel (black arrows) surrounded by astrocyte end-feet labeled with GFAP. (sections prepared by perfusion fixation,
e – labeled for GFAP with DAB staining, counterstained with toluidine blue, scale bar = 10 um).
Table 1 Percent occluded capillary vessels
12-hour 24-hour 36-hour 48-hour
Cortex 0% ± 5% 75% ± 10% 45% ± 5% 12% ± 2%
Hippocampus 0% ± 5% 25% ± 5% 80% ± 15% 40% ± 10%
Striatum 0% ± 5% 0% ± 5% 50% ± 8% 90% ± 10%
Semi-thin sections prepared at 12, 24, 36 and 48-hours after initiation of protein
diet showed substantial occlusion of capillary vessels in cortex, hippocampus and
striatum of Gcdh−/− but not Gcdh−/+ control brain. (n = 6 per time point, all
changes significant p < 0.001 compared to control).
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each brain region were examined for the status of capillary
lumina at different time points. Table 1 shows the pro-
portion of totally occluded or collapsed vessels in cor-
tex, striatum and hippocampus at different time points
(see methods). In the cortex more than 75% of total ca-
pillaries were occluded after 24-hours of protein diet
exposure (Table 1), however, less than 50% were
occluded at 36-hours, and less than 15% at 48-hours. In
hippocampal sections, less than 30% of total capillaries
were occluded at 24-hours, followed by an average of
80% occlusion at 36-hours and less than 50% at
48-hours (Table 1). In the striatum, there were no
occluded capillaries until 36-hours of protein diet
exposure when 50% were occluded, followed by 90%
occluded at 48-hours (Table 1). This pattern shows thatearly transient cortical ischemia is followed by more
severe ischemia in the striatum.
The quantity and severity of occluded vessels at differ-
ent time points observed by histology suggested a pat-
tern of ischemia that is likely detectable grossly in whole
brain. In order to capture these changes, Evans blue was
Figure 3 Ultrastructural vessel changes. Normal capillary morphology with surrounding astrocyte end-feet (arrow heads), neuronal projections,
identified by synapses (white arrows), and myelinated axons (black arrows) of Gcdh−/+ (a) and Gcdh−/− (b) mouse cortex after 72 and 12-hours
of protein diet exposure, respectively (see insets for enlargement of indicated sections). c Compressed capillary lumen surrounded by edematous
myelinated axons (thick black arrows) and dendrites (white arrows) with swelling mitochondria (thin black arrows) of Gcdh−/− mouse 24-hours
after initiation of protein diet. Note intact astrocyte process with nearly normal morphology (*) touching basal lamina of capillary lumen (arrow-
head). d Multiple edematous dendrites, identified by synapses (white arrows) and synaptic vesicles expand in proximity to capillary lumen with
adjacent astrocyte end-feet (arrowheads). e Compressed capillary surrounded by swollen astrocyte end-feet (black arrowheads) and edematous
neuronal projections identified by synapses (white arrows) both with swollen mitochondria. f Severely compromised capillary lumen in Gcdh−/−
mouse cortex at 48-hours of protein diet exposure surrounded by edematous dendrites identified by synapses (white arrows) and multiple
swollen mitochondria (thin black arrows) with compressed astrocyte end-feet (black arrowheads). (Perfusion fixed for EM, scale bar = 1 um).
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Figure 4 Bilateral ischemia and vessel changes in Gcdh−/− mouse brain after protein diet exposure. Comparison of Gcdh−/+ and Gcdh−/−
whole brain profile (a and f) with magnified cortical surface (inset), dorsal surface (b and g) and coronal section (c and h) with magnified areas
of cortex (d and i) and striatum (e and j) both placed on the protein diet for 72 and 36-hours respectively. Evans blue injection shows normal
vessel morphology with complete and smooth filling of cerebral vessels in Gcdh−/+ mouse. Inset (a) shows magnification of middle cerebral artery
branch (blue arrow) and pial veins (red arrows). Ischemia is noted as lack of blue staining (black arrows) in profile (f) and bilaterally on dorsal view
(g) and coronal section (h) of Gcdh−/− mouse. Inset (f) shows incomplete filling of middle cerebral artery branch (blue arrow) and differential
filling of pial vein branches (red arrows). Magnified areas of cortex and striatum (i and j) show prominence of non-exchange vessels (>10 μm,
white arrows) venous congestion (red arrows) and differential filling of return vessels (black arrows). (Evans blue protocol detailed in methods,
scale bar = 100 μm).
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and Gcdh−/+ control mice on the high protein diet.
Figure 4 shows a repeating pattern of ischemia at 36-
hours after protein diet exposure in Gcdh−/− mice, which
consistently showed pale ischemic regions of cortex and
striatum bilaterally (Figure 4f-h). These ischemic regions
are supplied via end branches of the middle cerebral artery
in each hemisphere. On closer inspection (Figure 4f inset)
evidence of shunting is found as venous end branches are
filling before arterial end branches. A similar pattern is
found in the cortex and striatum where non-exchange
vessels (larger than 10 μm) become prominent (Figure 4i
and j). Larger venules show congestion with differential
filling of end branches and surrounding areas of pale cor-
tex indicating lack of capillary bed filling (Figure 4i and j).
Compromised capillary bed perfusion and increased
blood–brain barrier permeability
We next used microscopic examination of Evans blue per-
fused brains to localize vascular changes associated with is-
chemic brain regions. Here we show loss of capillary bedperfusion within 36-hours of protein diet exposure in
Gcdh−/− mouse cortex and striatum (Figure 5). Larger
non-exchange vessels are shown with continued filling and
enlargement especially in striatum (Figure 5, lower panel).
Capillary bed perfusion continues to be severely limited at
48-hours in Gcdh−/− brain (Figure 5, far right), and back-
ground staining around vessels indicates increased blood–
brain barrier permeability. Additionally, continuity found
between larger non-exchange vessels is consistent with
shunting and early filling of the venous system found on
inspection of whole brain (Figure 4).
In order to quantify these changes, we measured Evans
blue concentration in perfused brain sections spectro-
photometrically. Evans blue content did not vary signifi-
cantly between Gcdh−/+ controls with and without the
protein diet. Therefore, concentrations are reported as
percentage of control after 72-hours of protein diet ex-
posure (Figure 5, bar graph). Both Gcdh−/− cortex and
cerebellum showed increased signal compared to control
before protein diet exposure. This difference is likely
associated with an increased baseline permeability of
Figure 5 Microscopic perfusion changes. Evans blue perfusion shows normal capillary bed network in cortex (top row) and striatum (bottom
row) of Gcdh−/+ control after 72-hours of protein diet and Gcdh−/− mice on standard diet. Note normal appearance of striatal arteries (black
arrows). After 36-hours of protein diet, Gcdh−/− mice show loss of capillary bed perfusion with continued filling of larger non-exchange vessels.
Note dilated striatal arteries (black arrows) and veins (white arrows). After 48-hours of protein diet exposure, capillary bed perfusion is limited with
prominence of larger non-exchange vessels. Note continuity between non-exchange vessels in cortex (arrows) and increased background signal
indicating permeability (scale bars = 200 μm). Bar graph) Gcdh−/− mouse brain samples from cortex (Ctx), striatum (Str), hippocampus (Hip) and
cerebellum (Cer) were evaluated for Evans blue concentration after standard (SD) or high protein (Pro) diet compared to Gcdh−/+ control.
(± S.E.M, * p < 0.05 compared to Gcdh−/+, # p < 0.05 compared to Gcdh−/− SD, n = 4 per group).
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campus all showed decreased signal compared to control
consistent with occluded vessels and lack of capillary bed
filling in Gcdh−/− brain 36-hours after protein diet ex-
posure (Figure 5). After 48 hours of protein exposure,
increased signal was found in all brain sections compared
to control, consistent with increased BBB permeability
after initial ischemia in these brain regions.
MRI angiography and perfusion
Based on the perfusion changes detected with Evans
blue injection, we reasoned that these differences may
be detectable with MR perfusion-weighted imaging and
MR angiography in vivo. Figure 6a and c shows relative
quantification of perfusion as index of cerebral blood
flow (ICBF) using a colorimetric scale. In WT mice therewas a slight increase in ICBF after 72-hours of lysine diet in
both cortex and striatum although not significant. Gcdh−/−
mice on a standard diet had significantly reduced cortical
ICBF compared to WT mice on a standard diet (Figure 6c).
After 96-hours of lysine diet exposure there was a substan-
tial decrease in ICBF both in the cortex and in the striatum
of Gcdh−/− mouse by 50% compared to standard diet
control (Figure 6a and c).
MR angiography showed reduced blood flow as a
complete loss of signal from cerebral vessels between
72-96-hours after lysine diet exposure in Gcdh−/−
mice. Figure 6b shows representative MR angiogram in
WT and Gcdh−/− mice on a standard diet, and Gcdh−/−
mouse after 96-hours of lysine diet. When an extended
acquisition time (TR = 100 ms) was used to maximize
the inflow signal and allow for slower blood flow to be
Figure 6 Magnetic resonance angiography and perfusion. Gcdh−/− and WT mice underwent MR perfusion-weighted imaging and angiog-
raphy before and after lysine diet exposure. a Representative images showing index of cerebral blood flow (ICBF) as colorimetric scale (0–600 ml/
100 mg tissue/ min). After 72-hours of lysine diet exposure, Gcdh−/− mouse shows reduced ICBF bilaterally in the striatum (ICBF < 300 ml/100 mg
tissue/min). After 96-hours, Gcdh−/− mouse has globally reduced ICBF (< 200 ml/100 mg tissue/min). b Normal visualization of circle of Willis, with
vertebral (VA), basilar (BA), posterior (PCA), middle (MCA) and anterior (ACA) cerebral arteries from bottom up in WT and Gcdh−/− mouse on a
standard diet (SD). Complete loss of signal in Gcdh−/− mouse brain is noted after 96-hours of lysine diet using standard acquisition time (19 ms).
Note signal from carotid arteries (large arrow) and circle of Willis (small arrow). Using 5-fold longer acquisition time (100 ms) a small area of the
posterior circulation is visible just above the carotid arteries (large arrow). c Quantitative ICBF changes were significant in cortical and striatal ICBF
in WT (n = 4) and Gcdh−/− mice (n = 5) following lysine diet exposure (* p < 0.05 t-test, **p < 0.05 ANOVA with repeated measures).
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basilar and posterior cerebral arteries were identified
(Figure 6b, far right). Taken together these results
suggest a bilateral, frontal greater than posterior deficit in
cerebral arterial flow associated with lysine diet exposure
in Gcdh−/− mice. These findings are consistent with our
Evans blue studies and previous findings in human
GA1 showing decreased perfusion during encephalo-
pathic crisis [28].Molecular basis of blood–brain barrier weakness
In the current study we have shown increased cerebral ca-
pillary permeability in Gcdh−/− mice consistent with previ-
ous findings [16]. We hypothesized that these pathological
features may be associated with an intrinsic weakness in
tight-junction proteins that form and maintain the BBB
[29,30]. Therefore, we tested the localization and relative
concentration of tight-junction proteins occludin and
ZO-1 in Gcdh−/− mice and Gcdh−/+ control. Here we
Figure 7 Confocal microscopy of blood–brain barrier. Cortical sections of perfusion fixed brain from Gcdh−/− and heterozygous (Gcdh−/+)
mice were fluorescently labeled for astrocytes with GFAP (green), occludin (red) and nuclei with DAPI (blue). a Gcdh−/+ mouse cortex shows
astrocyte end-feet (green) outlining larger blood vessel with complete ring of occludin between endothelial cells representing intact blood brain
barrier. b Similar section of Gcdh−/− mouse on a standard diet (SD) showing incomplete ring of occludin at blood–brain barrier. c Within 36-hours
of lysine diet exposure in the Gcdh−/− mouse, occludin is no longer between endothelial cells and appears to be withdrawn from the vessel
lumen. d After 6-weeks of lysine diet exposure in Gcdh−/− mice, signal from occludin is not detectable at blood–brain barrier. e and f VEGF was
significantly increased in cortex of Gcdh−/− mice compared to control and further increased after 36-hours of high lysine diet in cortex (e) and
striatum (f). (± S.E.M, ** p < 0.05 compared to standard diet control, * p < 0.02, n = 3-4 per group).
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after lysine diet exposure in Gcdh−/− mice (Figure 7).
Double labeled sections of Gcdh−/+ controls show
astrocyte end-feet (GFAP) extending to the cerebral
vessels with complete localization of occludin between
endothelial cells of the BBB (Figure 7a). In Gcdh−/−
mouse brain, incomplete occludin labeling is found at
the BBB on a standard diet for all brain sections exam-
ined (cortex, striatum and hippocampus) (Figure 7b).
After 36-hours of lysine diet exposure, occludin is
shown withdrawn from the cell borders in Gcdh−/−
mouse brain (Figure 7c). In Gcdh−/− mice that survive
the lysine diet and remain on the diet for 6 weeks,
complete loss of signal from occludin is shown
(Figure 7d). These changes were consistent in all brain
sections examined and show intrinsic weakness of theBBB in Gcdh−/− mice that is exacerbated with lysine
diet exposure. This weakness is shown to be associated
with loss of tight-junction protein occludin at the BBB.
Similar changes were not found for ZO-1 (Additional
file 1: Figure S1).
Recent work by Murakami and colleagues [31] demon-
strates a central role for occludin phosphorylation and
trafficking away from the BBB in VEGF mediated BBB
permeability. Based on the disruption of occludin
localization at the BBB in Gcdh−/− mice, we investigated
both VEGF levels and phosphorylation status of occludin
in control and Gcdh−/− mice with and without lysine diet
(Figure 7 and Additional file 1: Figure S1). VEGF, at
baseline, was significantly increased in the cortex of
Gcdh−/− mice compared to Gcdh−/+ control (Figure 7).
After 36-hours of lysine diet exposure VEGF was further
Figure 8 Mechanism of metabolic stroke. Metabolic dysfunction associated with glutaric acid production and accumulation results in
mitochondrial energy failure with secondary failure of Na/K ATPases and edema initially of neurons and neuronal projections (1). Neuronal
expansion impinges on capillary blood vessels leading to ischemia, which compounds and expands regions of neuronal swelling. Compression of
capillaries leads to shunting of blood to non-exchange vessels with early filling and dilation of the deep venous system (2). Lack of valves in cere-
bral veins allows for symmetric decreased flow from striatum and thalamus. Chronic metabolic dysfunction depletes α KG levels leading to lack of
HIF1a degradation and up regulation of VEGF leading to vessel expansion and weakness including mobilization of tight-junction proteins away
from blood–brain barrier (3). The combination of vessel impingement, shunting and weakened blood–brain barrier likely results in hemorrhages.
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increase in the phosphorylation status of occludin com-
pared to control (Additional file 1: Figure S1). VEGF was
also found to be elevated in the striatum after 36-hours,
providing additional support for a role of VEGF in the
abnormal localization of occludin (Figure 7) and in-
creased vascular permeability (Figure 5). These data are
consistent with incomplete occludin localization at the
BBB in Gcdh−/− mice and previous studies that showed
increased expression of VEGF in Gcdh−/− mouse brain
[32]. Testing for changes in hypoxia inducible factor 1
alpha (HIF1α) were inconclusive (data not shown). In-
creased VEGF has previously been associated with ische-
mic neurons [33], and is consistent with the evidence of
tissue ischemia presented in Table 1 and Figures 5 and6. Together these data suggest a mechanism of induced
BBB weakness and permeability in GA1.
Discussion
In this work we present several lines of evidence to show
that brain injury in GA1 involves a metabolic stroke, the
proposed mechanism of which is diagramed in Figure 8.
In contrast to ischemic stroke, metabolic stroke begins
with neuronal swelling associated with mitochondrial
failure. Neuronal vacuolation and swelling in cortex and
striatum was previously shown as the first neuropatho-
logical change in Gcdh−/− mice [17]. Here we show that
swelling of neuronal projections impinges on local capil-
lary vessels causing ischemia. Similar to ischemic stroke,
swelling of astrocyte end-feet after initial ischemia was
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Compromised capillary perfusion leads to shunting of
blood flow through non-exchange vessels with early fill-
ing of the venous system (Figure 8). These findings par-
allel perfusion changes and cerebral vessel enlargement,
found in human GA1 that predicted shunting of blood
to non-exchange vessels [4,28]. Early filling of the deep
brain venous system leads to expansion of these thin
walled vessels lacking support of a muscular media [34].
Similar findings have been reported for arterial venous
malformation of the basal ganglia where early filling of
the venous system was shown to cause dramatic expan-
sion to these vessels [25,26]. The lack of valves in the
cerebral venous system provides an even distribution of
symmetric expansion of these structures (Figure 8).
Combined with BBB weakness, increased pressure asso-
ciated with shunting and early filling of the venous sys-
tem likely accounts for hemorrhages in GA1.
Cerebrovascular weakness has been frequently reported
in GA1 as subdural and retinal hemorrhages, previously
misdiagnosed as non-accidental head trauma [8,10]. Simi-
larly, the GA1 mouse model has consistently shown devel-
opment of intracranial hemorrhages associated with
encephalopathic crisis when exposed to protein or lysine
diets that raise brain glutaric and 3-OH-glutaric acid levels
[16]. Previous in vitro studies have shown increased per-
meability of striatal but not cortical rat brain endothelial
cell monolayers exposed to glutaric and 3-OH-glutaric
acids [16]. Similar work by Muhlhausen and colleagues
showed disruption of human derived endothelial cells ex-
posed to 3-OH-glutaric acid [35]. The mechanism under-
lying a specific BBB weakness in GA1, however, has been
elusive. Initial evidence that VEGF may play a role in these
vascular anomalies came from microarray studies examin-
ing expression patterns in Gcdh−/− mouse brain that
showed increased expression of VEGF [32]. Recent data
by Murakami and coworkers demonstrates the pivotal role
of VEGF in mobilization of the tight-junction protein
occludin away from the BBB [31]. These data are consist-
ent with our current findings that VEGF is increased and
occludin is partially disrupted at baseline in the brain of
Gcdh−/− mice and may account as a possible mechanism
of BBB weakness in GA1.
Recent studies have shown that the interaction between
HIF1 α and VEGF can be modulated by the availability of
α KG [36]. In light of our previous findings that α KG
levels are depleted in the brain of Gcdh−/− mice, we can
now propose a mechanism to explain how metabolic dys-
function causes specific BBB weakness in GA1 [17]. As
diagramed in Figure 8, production of glutaric acid in the
brain is associated with depletion of α KG, which corre-
lates with decreased glutamate and γ -aminobutyric acid
(GABA) levels that are dependent on available α KG
[17,37]. Decreased α KG also leads to increased HIF1 α[36], which induces VEGF, already increased at baseline
and exacerbated further during encephalopathy. VEGF
stimulates phosphorylation and mobilization of occludin,
which allows for increased permeability and loss of integ-
rity of the BBB [31]. In the context of a failing BBB, the
increased pressure associated with shunting to non-
exchange vessels during encephalopathy likely accounts
for hemorrhages in GA1 [4,28].
Striatal injury is the hallmark of neuropathology in GA1
and other disorders presenting with metabolic stroke
[5,38,39]. Extrastriatal neuropathology involving the cor-
tical grey and white matter are also reported, but less rec-
ognized and studied [40,41]. Recent work by Harting and
colleagues follows MRI changes in pre-symptomatic GA1
patients and shows delay in early frontotemporal cortical
development that is already present at birth [42]. In the
majority of treated patients, this frontotemporal under-
development was shown to normalize by 4-years of age
[42]. In contrast, patients that experience encephalopathy
are more likely to show frontotemporal atrophy and
spongiform degeneration of white matter tracts [40-42].
Our current findings also show cortical involvement and
parallel findings in GA1 patients include evidence of de-
creased perfusion and glucose uptake in frontocortical
regions [4,28,40]. The GA1 mouse model may provide the
opportunity to further study and elucidate specific differ-
ences between cortical and striatal susceptibility.
In both mouse and human GA1 encephalopathy, the
cortex shows transient and more progressive degeneration
while the striatum is injured more rapidly and completely
[42]. Similar findings were shown to be associated with the
brain regions most affected by BBB breakdown in models
of transient middle cerebral artery occlusion as well as
metabolic inhibition [43,44]. Striatal degeneration is the
most consistent neuropathological finding in GA1 [42],
however, our current findings and other models of ische-
mic and metabolic stroke show that cortical involvement
typically precedes and exacerbates striatal damage [44,45].
Indeed, striatal injury can be alleviated by removal of cor-
tical projections [45-47]. Consistent with our current and
previous findings, cortical neurons are more likely to re-
cover as striatal neurons are further compromised parallel-
ing the level of BBB damage [16,48,49]. Striatal neurons
are especially at risk because of the high concentration of
N-methyl-D-aspartate (NMDA) receptors and cortico-
striatal glutamatergic projections as well as specific BBB
vulnerability [16,50]. Previous studies have shown the se-
lective vulnerability of the striatum to uncontrolled excita-
tory amino acid exposure causing excitotoxicity [51]. We
and others have shown the specific vulnerability of the stri-
atal BBB to metabolic and toxic insult as well as transient
ischemic stroke [16,44,49]. Taken together, cortical insult
and BBB compromise could account for selective striatal
vulnerability. BBB compromise, as seen in this model,
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which can lead to both acute and chronic neuronal injury
with progressive degeneration seen in both mouse and hu-
man GA1. This mechanism could be in part responsible
for bilateral striatal necrosis that develops over 6-weeks in
adult Gcdh−/− mice surviving on a high lysine diet where
BBB occludin is undetectable [16].
Conclusions
In the current study we have characterized metabolic
stroke in a mouse model of GA1 showing initial neur-
onal swelling with secondary ischemia associated with
impingement of brain capillaries. Capillary occlusion
leads to shunting of blood to non-exchange vessels with
early filling and dilation of the venous system. Loss of
the tight-junction protein, occludin, is shown as an in-
trinsic weakness of the BBB exacerbated by metabolic
encephalopathy. Together these findings may account
for the intracranial hemorrhages frequently encountered
in Gcdh−/− mice, and GA1 patients, and suggest poten-
tial new targets for preventive strategies. Previous work
by Antonetti and colleagues showed hydrocortisone
treatment of endothelial cells in vitro was associated
with increased occludin localization at tight-junction
barriers and decreased permeability [52]. These findings
suggest a potential role for hydrocortisone treatment to
improve BBB integrity in GA1.
Additional file
Additional file 1: Figure S1. Brain tissue Western blot analysis.
Representative western blot analysis for brain protein extracts from Gcdh−/−
and wild type (WT) mice placed on the lysine (Lys) diet for 36-hours.
Phosphorylated Occludin data tabulated at lower right. (n = 3-4 samples per
group, *p < 0.05 compared to WT).
Competing interests
The authors declare that they have no competing interests regarding data
presented in this manuscript.
Authors’ contributions
Experiments were done by WZ, JL, CH, and DA. Data were analyzed by WZ,
JL, CH, DA, DK, JC and LS. Paper was written by WZ, JL, DA, DK, JC and LS.
All authors read and approved the final manuscript.
Acknowledgements
This work is dedicated to the memory of Michael Metil, whose persistent
smile and dedicated parents taught us the importance of collaboration in
the name of preventing further injury from GA1. We thank the Laverty and
Oxford Foundations, the International Organization of Glutaric Aciduria, and
the Maple syrup urine disease family support group as well as NINDS F32
Fellowship award, NS581642, to JL for support of this work.
Author details
1Department of Neurology and Neurological Science, Stanford University,
Stanford, CA 94305, USA. 2Department of Radiology, University of California,
Los Angeles, CA 90095, USA. 3Department of Pathology, Penn State College
of Medicine, Hershey, PA, USA. 4Department of Ophthalmology and Visual
Sciences, Molecular and Integrative Physiology, University of Michigan, Ann
Arbor, MI, USA. 5Departments of Pediatrics, and Molecular and Medical
Genetics, Oregon Health & Science University, Portland, OR, USA.6Department of Neurosurgery, Penn State College of Medicine, Hershey, PA,
USA.
Received: 9 January 2014 Accepted: 18 January 2014
Published: 27 January 2014
References
1. Sutherland GR, Auer RN: Primary intracerebral hemorrhage. J Clin Neurosci
2006, 13(5):511–517. doi: 10.1016/j.jocn.2004.12.012.
2. Barber PA, Auer RN, Buchan AM, Sutherland GR: Understanding and
managing ischemic stroke. Can J Physiol Pharmacol 2001, 79(3):283–296.
3. Schreiber J, Chapman KA, Summar ML, Ah Mew N, Sutton VR, MacLeod E,
Stagni K, Ueda K, Franks J, Island E, Matern D, Pena L, Smith B, Urv T, Venditti C,
Chakarapani A, Gropman AL: Neurologic considerations in propionic
acidemia. Mol Genet Metab, 105(1):10–15. doi: 10.1016/j.ymgme.2011.10.003.
4. Strauss KA, Lazovic J, Wintermark M, Morton DH: Multimodal imaging of
striatal degeneration in Amish patients with glutaryl-CoA dehydrogenase
deficiency. Brain 2007, 130(Pt 7):1905–1920. doi: 10.1093/brain/awm058.
5. Hoffmann GF, Gibson KM, Trefz FK, Nyhan WL, Bremer HJ, Rating D:
Neurological manifestations of organic acid disorders. Eur J Pediatr 1994,
153(7 Suppl 1):S94–S100.
6. Dave P, Curless RG, Steinman L: Cerebellar hemorrhage complicating
methylmalonic and propionic acidemia. Arch Neurol 1984, 41(12):1293–1296.
7. Woelfle J, Kreft B, Emons D, Haverkamp F: Subdural hemorrhage as an
initial sign of glutaric aciduria type 1: a diagnostic pitfall. Pediatr Radiol
1996, 26(11):779–781.
8. Hartley LM, Mrcp B, Khwaja OS, Verity CM, Frcpch B: Glutaric aciduria type
1 and nonaccidental head injury. Pediatrics 2001, 107(1):174–175.
9. Kolker S, Garbade SF, Greenberg CR, Leonard JV, Saudubray JM, Ribes A,
Kalkanoglu HS, Lund AM, Merinero B, Wajner M, Troncoso M, Williams M,
Walter JH, Campistol J, Marti-Herrero M, Caswill M, Burlina AB, Lagler F,
Maier EM, Schwahn B, Tokatli A, Dursun A, Coskun T, Chalmers RA, Koeller
DM, Zschocke J, Christensen E, Burgard P, Hoffmann GF: Natural history,
outcome, and treatment efficacy in children and adults with glutaryl-
CoA dehydrogenase deficiency. Pediatr Res 2006, 59(6):840–847.
10. Strauss KA, Puffenberger EG, Robinson DL, Morton DH: Type I glutaric
aciduria, part 1: natural history of 77 patients. Am J Med Genet C: Semin Med
Genet 2003, 121(1):38–52.
11. Goodman SI, Frerman FE: Organic Acidemias due to defects in lysine
oxidation: 2-ketoadipic academia and glutaric academia. In The metabolic
and molecular bases of inherited disease. 3rd edition. Edited by Scriver C,
Beudet A, Sly W, Valle D. New York: McGraw Hill; 1995:2195–2204.
12. Kyllerman M, Steen G: Glutaric aciduria. A “common” metabolic disorder?
Arch Fr Pediatr 1980, 37(4):279.
13. Van Der Watt G, Owen EP, Berman P, Meldau S, Watermeyer N, Olpin SE,
Manning NJ, Baumgarten I, Leisegang F, Henderson H: Glutaric aciduria
type 1 in South Africa-high incidence of glutaryl-CoA dehydrogenase
deficiency in black South Africans. Mol Genet Metab, 101(2–3):178–182.
doi: 10.1016/j.ymgme.2010.07.018.
14. Haworth JC, Booth FA, Chudley AE, deGroot GW, Dilling LA, Goodman SI,
Greenberg CR, Mallory CJ, McClarty BM, Seshia SS, Seargeant LE: Phenotypic
variability in glutaric aciduria type I: Report of fourteen cases in five
Canadian Indian kindreds. J Pediatr 1991, 118(1):52–58.
15. Naughten ER, Mayne PD, Monavari AA, Goodman SI, Sulaiman G, Croke DT:
Glutaric aciduria type I: outcome in the Republic of Ireland. J Inherit Metab
Dis 2004, 27(6):917–920. doi: 10.1023/B:BOLI.0000045777.82784.74.
16. Zinnanti WJ, Lazovic J, Wolpert EB, Antonetti DA, Smith MB, Connor JR, Woontner
M, Goodman SI, Cheng KC: A diet-induced mouse model for glutaric aciduria
type I. Brain 2006, 129(Pt 4):899–910.
17. Zinnanti WJ, Lazovic J, Housman C, LaNoue K, O’Callaghan JP, Simpson I,
Woontner M, Goodman SI, Connor JR, Jacobs RE, Cheng KC: Mechanism of
age-dependent susceptibility and novel treatment strategy in glutaric
acidemia type I. J Clin Invest 2007, 117(11):3258–3270.
18. Koeller DM, Woontner M, Crnic LS, Kleinschmidt-DeMasters B, Stephens J, Hunt
EL, Goodman SI: Biochemical, pathologic and behavioral analysis of a mouse
model of glutaric acidemia type I. Hum Mol Genet 2002, 11(4):347–357.
19. Benevenga NJ, Steele RD: Adverse effects of excessive consumption of amino
acids. Annu Rev Nutr 1984, 4:157–181.
20. Tsubuku S, Mochizuki M, Mawatari K, Smriga M, Kimura T: Thirteen-week
oral toxicity study of L-lysine hydrochloride in rats. Int J Toxicol 2004,
23(2):113–118.
Zinnanti et al. Acta Neuropathologica Communications 2014, 2:13 Page 15 of 15
http://www.actaneurocomms.org/content/2/1/1321. Franklin KBJ, Paxinos G: The mouse brain in steriotaxic coordinates. 2nd edition.
San Diego, Ca: Academic Press, Inc.; 1997.
22. Blinder P, Shih AY, Rafie C, Kleinfeld D: Topological basis for the robust
distribution of blood to rodent neocortex. Proc Natl Acad Sci USA,
107(28):12670–12675. doi: 10.1073/pnas.1007239107.
23. Del Bigio MR, Yan HJ, Kozlowski P, Sutherland GR, Peeling J: Serial magnetic
resonance imaging of rat brain after induction of renal hypertension.
Stroke 1999, 30(11):2440–2447.
24. Sundstrom JM, Tash BR, Murakami T, Flanagan JM, Bewley MC, Stanley BA,
Gonsar KB, Antonetti DA: Identification and analysis of occludin
phosphosites: a combined mass spectrometry and bioinformatics
approach. J Proteome Res 2009, 8(2):808–817. doi: 10.1021/pr7007913.
25. Osborn AG: Diagnostic neuroradiology [print]. 1st edition. St. Louis: Mosby; 1994.
26. Papapetropoulos S, Singer C, Sengun C, Gallo BV: Giant arteriovenous
malformation presenting as pediatric task-specific dystonia. Neurology
2008, 70(15):1294. doi: 10.1212/01.wnl.0000306637.14628.76.
27. Ito U, Hakamata Y, Kawakami E, Oyanagi K: Temporary [corrected] cerebral
ischemia results in swollen astrocytic end-feet that compress microvessels
and lead to delayed [corrected] focal cortical infarction. J Cereb Blood Flow
Metab 2011, 31(1):328–338. doi: 10.1038/jcbfm.2010.97.
28. Strauss KA, Donnelly P, Wintermark M: Cerebral haemodynamics in
patients with glutaryl-coenzyme A dehydrogenase deficiency. Brain 2010,
133(Pt 1):76–92. doi: 10.1093/brain/awp297.
29. Citi S, Cordenonsi M: Tight junction proteins. Biochim Biophys Acta 1998,
1448(1):1–11.
30. Denker BM, Nigam SK: Molecular structure and assembly of the tight
junction. Am J Physiol 1998, 274(1 Pt 2):F1–F9.
31. Murakami T, Felinski EA, Antonetti DA: Occludin phosphorylation and
ubiquitination regulate tight junction trafficking and vascular endothelial
growth factor-induced permeability. J Biol Chem 2009, 284(31):21036–21046.
doi: 10.1074/jbc.M109.016766.
32. Muhlhausen C, Ergun S, Strauss KA, Koeller DM, Crnic L, Woontner M, Goodman
SI, Ullrich K, Braulke T: Vascular dysfunction as an additional pathomechanism
in glutaric aciduria type I. J Inherit Metab Dis 2004, 27(6):829–834.
33. Jin KL, Mao XO, Nagayama T, Goldsmith PC, Greenberg DA: Induction of
vascular endothelial growth factor and hypoxia-inducible factor-1alpha
by global ischemia in rat brain. Neuroscience 2000, 99(3):577–585.
34. Kilic T, Akakin A: Anatomy of cerebral veins and sinuses. Front Neurol
Neurosci 2008, 23:4–15. doi: 10.1159/0000111256.
35. Muhlhausen C, Ott N, Chalajour F, Tilki D, Freudenberg F, Shahhossini M,
Thiem J, Ullrich K, Braulke T, Ergun S: Endothelial effects of 3-hydroxyglutaric
acid: implications for glutaric aciduria type I. Pediatr Res 2006, 59(2):196–202.
doi: 10.1203/01.pdr.0000197313.44265.cb.
36. Matsumoto K, Imagawa S, Obara N, Suzuki N, Takahashi S, Nagasawa T,
Yamamoto M: 2-Oxoglutarate downregulates expression of vascular
endothelial growth factor and erythropoietin through decreasing
hypoxia-inducible factor-1alpha and inhibits angiogenesis. J Cell Physiol
2006, 209(2):333–340. doi: 10.1002/jcp.20733.
37. Stokke O, Goodman SI, Moe PG: Inhibition of brain glutamate decarboxylase
by glutarate, glutaconate, and beta-hydroxyglutarate: explanation of the
symptoms in glutaric aciduria? Clin Chim Acta 1976, 66(3):411–415.
38. Strauss KA, Morton DH: Type I glutaric aciduria, part 2: a model of acute
striatal necrosis. Am J Med Genet C: Semin Med Genet 2003, 121(1):53–70.
39. Hamilton RL, Haas RH, Nyhan WL, Powell HC, Grafe MR: Neuropathology of
propionic acidemia: a report of two patients with basal ganglia lesions.
J Child Neurol 1995, 10(1):25–30.
40. Al-Essa M, Bakheet S, Patay Z, Al-Watban J, Powe J, Joshi S, Ozand PT:
Fluoro-2-deoxyglucose (18FDG) PET scan of the brain in glutaric aciduria
type 1: clinical and MRI correlations. Brain Dev 1998, 20(5):295–301.
41. Baric I, Zschocke J, Christensen E, Duran M, Goodman SI, Leonard JV, Muller
E, Morton DH, Superti-Furga A, Hoffmann GF: Diagnosis and management
of glutaric aciduria type I. J Inherit Metab Dis 1998, 21(4):326–340.
42. Harting I, Neumaier-Probst E, Seitz A, Maier EM, Assmann B, Baric I, Troncoso
M, Muhlhausen C, Zschocke J, Boy NP, Hoffmann GF, Garbade SF, Kolker S:
Dynamic changes of striatal and extrastriatal abnormalities in glutaric
aciduria type I. Brain 2009, 132(Pt 7):1764–1782. doi: 1093/brain/awp112.
43. Hamilton BF, Gould DH: Correlation of morphologic brain lesions with
physiologic alterations and blood–brain barrier impairment in 3-
nitropropionic acid toxicity in rats. Acta Neuropathol 1987, 74(1):67–74.44. Nishino H, Czurko A, Fukuda A, Hashitani T, Hida H, Karadi Z, Lenard L:
Pathophysiological process after transient ischemia of the middle
cerebral artery in the rat. Brain Res Bull 1994, 35(1):51–56.
45. Fu Y, He F, Zhang S, Huang J, Zhang J, Jiao X: 3-Nitropropionic acid
produces indirect excitotoxic damage to rat striatum. Neurotoxicol Teratol
1995, 17(3):333–339.
46. Linden T, Kalimo H, Wieloch T: Protective effect of lesion to the
glutamatergic cortico-striatal projections on the hypoglycemic nerve cell
injury in rat striatum. Acta Neuropathol 1987, 74(4):335–344.
47. McGeer EG, McGeer PL, Singh K: Kainate-induced degeneration of
neostriatal neurons: dependency upon corticostriatal tract. Brain Res
1978, 139(2):381–383.
48. Nishino H, Czurko A, Onizuka K, Fukuda A, Hida H, Ungsuparkorn C,
Kunimatsu M, Sasaki M, Karadi Z, Lenard L: Neuronal damage following
transient cerebral ischemia and its restoration by neural transplant.
Neurobiology (Bp) 1994, 2(3):223–234.
49. Hamilton BF, Gould DH: Nature and distribution of brain lesions in rats
intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient)
brain damage. Acta Neuropathol (Berl) 1987, 72(3):286–297.
50. Johnston MV, Trescher WH, Ishida A, Nakajima W: Neurobiology of hypoxic-
ischemic injury in the developing brain. Pediatr Res 2001, 49(6):735–741.
51. Calabresi P, Centonze D, Gubellini P, Marfia GA, Pisani A, Sancesario G,
Bernardi G: Synaptic transmission in the striatum: from plasticity to
neurodegeneration. Prog Neurobiol 2000, 61(3):231–265.
52. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr: Hydrocortisone
decreases retinal endothelial cell water and solute flux coincident with
increased content and decreased phosphorylation of occludin. J Neurochem
2002, 80(4):667–677.
doi:10.1186/2051-5960-2-13
Cite this article as: Zinnanti et al.: Mechanism of metabolic stroke and
spontaneous cerebral hemorrhage in glutaric aciduria type I. Acta
Neuropathologica Communications 2014 2:13.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
